Impact of Monthly 120 mg Denosumab on Bone Metabolism in Bone-metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy

Impact of Monthly 120 mg Denosumab on Bone Metabolism in Bone-metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy

Show other versions (1)

Background: While semiannual 60 mg denosumab is a common treatment for osteoporosis, the impact of monthly 120 mg denosumab, the common treatment protocol for bone metastases from solid tumors, on bone metabolism is unclear. Materials and Methods: We reviewed 15 patients with bone-metastatic prostat...

Full description

Bibliographic Details
Main Authors: Jimpei Miyakawa, Satoru Taguchi, Motofumi Suzuki, Kaori Endo, Yorito Nose, Toshikazu Sato, Akira Ishikawa, Hiroshi Fukuhara, Yukio Homma
Format: Article
Language:English
Published: West Asia Organization for Cancer Prevention 2017-08-01
Series:Asian Pacific Journal of Cancer Care
Online Access:http://www.waocp.org/journal/index.php/apjcc/article/view/94

Internet

http://www.waocp.org/journal/index.php/apjcc/article/view/94

Similar Items